The adaptor protein Disabled-2: new insights into platelet biology and integrin signaling by Hui-Ju Tsai & Ching-Ping Tseng
The Author(s) Thrombosis Journal 2016, 14(Suppl 1):28
DOI 10.1186/s12959-016-0101-5REVIEW Open AccessThe adaptor protein Disabled-2: new
insights into platelet biology and integrin
signaling
Hui-Ju Tsai1,2 and Ching-Ping Tseng1,2,3,4*From The 9th Congress of the Asian-Pacific Society on Thrombosis and Hemostasis
Taipei, Taiwan. 6-9 October 2016Abstract
Multiple functions of platelets in various physiological and pathological conditions have prompted considerable
attention on understanding how platelets are generated and activated. Of the adaptor proteins that are expressed in
megakaryocytes and platelets, Disabled-2 (Dab2) has been demonstrated in the past decades as a key regulator of
platelet signaling. Dab2 has two alternative splicing isoforms p82 and p59. However, the mode of Dab2’s action
remains to be clearly defined. In this review, we highlight the current understanding of Dab2 expression and function
in megakaryocytic differentiation, platelet activation and integrin signaling. Accordingly, Dab2 is upregulated when the
human K562 cells, human CD34+ hematopoietic stem cells, and murine embryonic stem cells were undergone
megakaryocytic differentiation. Appropriate level of Dab2 expression is essential for fate determination of mesodermal
and megakaryocytic differentiation. Dab2 is also shown to regulate cell-cell and cell-fibrinogen adhesion, integrin
αIIbβ3 activation, fibrinogen uptake, and intracellular signaling of the megakaryocytic cells. In human platelets, p82 is
the sole Dab2 isoform present in the cytoplasm and α-granules. Dab2 is released from the α-granules and forms two
pools of Dab2 on the outer surface of the platelet plasma membrane, one at the sulfatide-bound and the other at
integrin αIIbβ3-bound forms. The balance between these two pools of Dab2 controls the extent of clotting reaction,
platelet-fibrinogen interactions and outside-in signaling. In murine platelets, p59 is the only Dab2 isoform and is
required for platelet aggregation, fibrinogen uptake, RhoA-ROCK activation, adenosine diphosphate release and
integrin αIIbβ3 activation stimulated by low concentration of thrombin. As a result, the bleeding time is prolonged and
thrombus formation is impaired for the megakaryocyte lineage-restricted Dab2 deficient mouse. Although
discrepancies of Dab2 function and isoform expression are noted between human and murine platelets, the studies
up-to-date define Dab2 playing a pivotal role in integrin signaling and platelet activation. With the new tools such as
CRISPR and TALEN in the generation of genetically modified animals, the progress in gaining new insights into the
functions of Dab2 in megakaryocyte and platelet biology is expected to accelerate.
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Platelets are the second most abundant blood cells and are
derived from the cytoplasm of megakaryocytes [1]. The
crucial role of platelet in haemostasis and thrombosis has
prompted extensive attentions on unveiling the underlying
mechanisms of platelet activation induced by soluble ago-
nists [2–4]. Platelet activation is mainly mediated by bind-
ing of ligands to the membrane receptors such as the
immunoglobulin family of glycoproteins for collagen and
the G-protein coupled receptors for thrombin, thromb-
oxane A2 (TXA2) and adenosine diphosphate (ADP) [5].
Collagen interacts with glycoprotein VI which contains an
immunoreceptor tyrosine-based activation motif (ITAM).
The ITAM is phosphoryated by two Src kinases (Lyn and
Fyn) and recruits the protein tyrosine kinase Syk to the
plasma membrane for phosphorylation of downstream
substrates at the tyrosine residue that are essential for
platelet activation [5]. Other soluble agonists such as
thrombin, TXA2 and ADP bind to the respective G
protein-coupled receptors and cause an increase in intra-
cellular calcium and protein kinase C (PKC) activity, Rho
activation, inhibition of adenylyl cyclase and activation of
phosphoinositide 3-kinase-Akt through the Gαq-, Gα12/13-,
Gαi-, and Gβγ-dependent pathway, respectively [5, 6]. The
inside-out signaling induced by different platelet agonists
activates integrin αIIbβ3 followed by the binding of fibrino-
gen to integrin αIIbβ3 and activation of outside-in signal-
ing. These intracellular events ultimately lead to platelet
activation, secretion and aggregation [7]. Despite extensive
studies, the underlying mechanisms of platelet signaling
networks still wait to be fully elucidated.
Adaptor protein is a type of proteins mediating protein-
protein and protein-lipid interactions. It has been clearly
demonstrated that adaptor proteins are essential for coup-
ling membrane receptors to intracellular signaling path-
ways and the assembly of signaling scaffolds within the
cells. Many adaptor proteins expressed in the platelets are
involved in inside-out and outside-in signaling of integrin
during platelet activation [8]. Disabled-2 (Dab2) is a newly
identified adaptor protein that is known to express in
megakaryocytes and platelets from a variety of species
[9, 10]. The current knowledge about the roles of Dab2 in
megakaryocytic differentiation and platelet signaling is still
in the beginning. This review will focus on the expression
and functional aspects of Dab2 in megakaryocytic differ-
entiation, platelet activation and integrin signaling.Review
Discovery and the protein properties of Dab2
Human dab2 gene is located at the chromosome 5p13
and was first identified by Mok et al. as the tumor sup-
pressor gene of the ovary cancer in 1994 [11]. The mouse
Dab2 protein was then revealed in 1995 during the ana-
lysis of phosphoproteins induced by colony-stimulating
factor-1 (CSF-1) in macrophage [12]. In 1998, Tseng et al.
further defined rat dab2 as the differentially expressed
gene that was up-regulated in the castrated rat prostate
[13]. At least two Dab2 isoforms with the molecular
weight of 82 and 59 kDa, referred to p82-Dab2 and
p59-Dab2, respectively, are generated through alternative
splicing (Fig. 1) [14]. Because of the undefined post-
translational protein modification, the protein bands of
p82-Dab2 and p59-Dab2 are up-shifted to the positions at
96 and 67 kDa on sodium dodecyl sulfate-polyacrylamide
gel electrophoresis. Hence, p82-Dab2 and p59-Dab2
sometimes are referred to p96-Dab2 and p67-Dab2,
respectively. The ninth coding exon corresponding to the
amino acids 230–447 of p82-Dab2 is not present in the
protein of p59-Dab2. As a result, several binding sites for
endocytic proteins are absent in p59-Dab2. Particular mo-
tifs mediating protein-protein and protein-lipid interac-
tions are present in Dab2, allowing them to communicate
with other signaling molecules. The phosphotyrosine
binding (PTB) domain is located at the N-terminus of
Dab2, playing a role in the interaction of Dab2 with
DIP1/2, Smad2/3, Dishevelled-3, phosphatidylinositol
4,5-bisphosphate (PI(4,5)P2), and a subset of receptors
such as integrin, low density lipoprotein receptor, megalin
and related receptors that contain the non-tyrosine-
phosphorylated NPXY motif [14–21]. The aspartic acid-
proline-phenylalanine (DPF) motif of Dab2 interacts with
the α-adaptin subunit of the clathrin adaptor protein 2
(AP-2) [21]. The C-terminal proline-rich domain (PRD)
interacts with Grb2, c-Src, Akt and c-Cbl-interacting pro-
tein of 85 kDa [22–26]. By interacting with other cellular
factors through these motifs, Dab2 elicits its functions in
endocytosis, differentiation, and immune response and is
involved in the cell signaling pathways of Ras-mitogen
activated protein kinase (MAPK), Wnt, TGF-β, c-Src
and RhoA-ROCK [24, 27–36]. Dab2 is also known to
regulate cytoskeleton reorganization by binding to non-
muscle myosin heavy chain IIA, myosin VI, actin, and
dynein [12, 37–39].
Fig. 1 Schematic illustration for the primary protein structure of Dab2. The primary structures for both Dab2 isoforms p82 (p96) and p59 (p67) are
shown. The p59 (p67) isoform of Dab2 lacks the ninth coding exon corresponding to the amino acid residues of 230–447 and results in the deletion
of several binding sites for endocytic proteins. The N-terminus of Dab2 contains an actin-binding motif (25KKEK28), two sulfatide binding sites (amino
acid residues 24–32 and 49–54), an RGD motif (64RGD66), one thrombin cleavage site (64R) and the PTB domain (amino acid residues 45–196). Dab2-PTB is
the binding sites for PI(4,5)P2 and the tails of a subset of non-tyrosine-phosphorylated NPXY-containing receptors. The clathrin type I (
236LVDLN240) and
type II (363PWPFS367) box sequences, and the two DPF motifs (293DPFRDDPF300) are located at the middle region of Dab2 protein. The DPF motifs bind
to the α-adaptin subunit of the clathrin adaptor protein AP-2. The five asparagine-proline-phenylalanine (NPF) motifs spanning the middle and C-
terminus of Dab2 possibly bind proteins containing Eps homology domain. The C-terminus of Dab2 contains the myosin VI binding domain and the
PRD for the binding of proteins containing SH3 domain
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sites having been identified. Dab2 is phosphorylated at
serine residues in murine macrophage cell line in re-
sponse to mitogenic stimulation by CSF-1 [12]. Dab2-
Ser24 is phosphorylated by PKCβII, γ and δ but not by
casein kinase II, playing a critical role in the inhibition
of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced
AP-1 activity and integrin activation [33, 40]. Dab2 is
hyperphosphorylated by the cyclin-dependent serine/
threonine kinase Cdc2 during the mitosis phase of the
cell cycle in HeLa S3 cells [41]. The phosphorylated
Dab2 interacts with the peptidylprolyl isomerase Pin1
that facilitates Dab2 dephosphorylation immediately
after the end of mitosis phase [42]. Similarly, Akt inter-
acts with PRD domain of Dab2 and phosphorylates
Ser448/Ser449 to regulate albumin endocytosis and me-
diate albumin uptake in proximal tubule [25, 43]. These
distinct protein properties facilitate the involvement of
Dab2 in diverse signaling network in response to extra-
cellular responses.
Expression pattern of Dab2 in megakaryocytes and
platelets
The first study addressing Dab2 expression and function
in megakaryocytes and platelets was published in 2001
[31]. Dab2 is upregulated when the human leukemic K562
cells, human CD34+ hematopoietic pluripotent stem cells,
and murine embryonic stem cells (ESCs) are undergonemegakaryocytic differentiation (Table 1) [31–33, 35].
Among the platelets from the species of murine, rat, and
human, murine platelets have the least amount of Dab2
[9]. This is in accord with the genome-wide RNA-seq ana-
lysis of platelet transcriptomes that revealed several
thousands-fold differences for the expression of Dab2
transcripts between human and mouse platelets [44].
Moreover, Dab2 isoforms are differentially expressed in
human, rat and murine platelets. Both p82-Dab2 and p59-
Dab2 are detectable in the rat platelets, while p82-Dab2
and p59-Dab2 is mainly expressed in the platelets from
human and murine, respectively [9].
The evolutionary roles for an increase in Dab2 expres-
sion from mouse to rat and human platelets and the
species-specific expression of Dab2 isoforms are not yet
understood. Distinctive functions of p82-Dab2 and p59-
Dab2 have been unveiled in several studies. p82-Dab2 is
known to regulate receptor-mediated endocytosis, while
p59-Dab2 is a transcriptional regulator when the F9 cells
are undergone differentiation [18, 20, 45, 46]. Knock-in
expression of p59-Dab2 only partially compromises the
absence of Dab2 in the Dab2-knockout mice [14]. The in-
creased expression of p82-Dab2 protein in human plate-
lets may fine tune platelet response to soluble agonists
and provide a superior way to prevent excessive blood loss
in the large mammals. Future study using an in vivo ani-
mal model expressing human platelet p82-Dab2 should
provide new insight for the aforementioned hypothesis.
Table 1 Dab2 expression and function in megakaryocytes and
platelets
Experimental systems Reported Dab2 expression/function References




Positive regulation of fibrinogen
uptake
Dab2 interacts with integrin β3















Dab2 is required for mesodermal
differentiation
Human platelets High expression of p82-Dab2 in
the cytoplasm and α-granule
[10, 33,
47–49]
Dab2 interacts with the cytoplamic
tail of platelet integrin
Secreted Dab2 interacts with
integrin αIIb and sulfatide; is
a substrate of thrombin
Dab2 regulates fibrinogen binding
and homotypic and heterotypic
platelet interactions
Mouse platelets Low expression of p59-Dab2 [9]
Dab2-deficient mice display a
prolonged bleeding time and
impaired thrombus formation
Dab2 is required for platelet
aggregation, fibrinogen
uptake, RhoA-ROCK activation,
ADP release and integrin αIIbβ3
activation stimulated by low
concentration of thrombin
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platelet signaling
Dab2 has been shown to elicit multiple functions in mega-
karyocytic differentiation and platelet signaling (Table 1
and Fig. 2). The human K562 leukemic cells induced by
TPA to form megakaryocyte-like cells have been used to
define the role of Dab2 in integrin activation, cell adhe-
sion, fibrinogen uptake, and megakaryocytic differenti-
ation [31–34]. Dab2 is crucial in cell-cell adhesion of
K562 cells and negatively regulates integrin αIIbβ3 activa-
tion and cell adhesion to fibrinogen. A mutual regulation
between Dab2 and MAPK was also unveiled when the
K562 cells are undergone megakaryocytic differentiation
[31, 32]. Dab2 colocalizes with clathrin and mediates
fibrinogen uptake in the primary megakaryocytes and
megakaryocytic differentiating K562 cells [34]. Dab2-associated regulatory circuit controls mesoderm and
megakaryocytic differentiation by regulating β-catenin and
plakoglobin cellular distribution through the interaction
between the PTB domain of Dab2 and the Asn-Pro-
Asp-Tyr motif of plakoglobin [35]. Accordingly, down-
regulation of Dab2 in murine ESCs disrupts cell-cell
adhesion and affects embryoid body and colony formation
leading to impaired mesodermal and megakaryocytic
differentiation. Multiple roles of Dab2 in intracellular
signaling, integrin activation and fibrinogen uptake of the
megakaryocytic cells, and the fate determination of
mesodermal and megakaryocytic differentiation were de-
fined by these studies.
Dab2 is present in the cytoplasm and α-granules of
human platelets and is released from the platelets in
response to platelet activation [10]. Dab2 is shown in a
number of studies playing a pivotal role in the activation
of human platelets. Dab2 interacts with the cytoplasmic
tail of the platelet integrin and regulates inside-out
signaling [33]. On the other hand, Dab2 released from
the α-granules is able to bind the extracellular region of
αIIbβ3 integrin through the Dab2 cell-adhesion Arg-
Gly-Asp (RGD) motif (amino acid residues 64–66) and
the fibrinogen binding region of integrin αIIb. Such in-
teractions compete for the integrin αIIb-fibrinogen
interactions and inhibit platelet aggregation induced by
soluble agonists except thrombin. Thrombin renders
Dab2 inactive by cleavage of Dab2 at the amino acid
residue 64 [10]. Notably, the action of thrombin on
Dab2 cleavage is suppressed when Dab2 binds to the
phospholipid sulfatide through four positively charged
residues (Lys25, Lys49, Lys51, and Lys53) located at the
PTB domain [47]. Hence, two pools of Dab2 is present
at the outer surface of the platelet plasma membrane,
one at the sulfatide-bound and the other at the integrin
αIIbβ3-bound states. The balance between these two
Dab2 states is involved in the regulation of clotting reac-
tion, platelet aggregation and the interactions of platelet
and fibrinogen in response to stimulation by platelet
agonists [10, 47–49].
Megakaryocyte/platelet lineage-restricted Dab2 knock-
out (Dab2-/-) mice have been generated by using the
Cre-loxP transgenic system driven by the platelet factor
4 promoter to elucidate Dab2 functions in vivo [9].
Dab2-/- platelets, when stimulated by low concentrations
of thrombin, are defective in platelet aggregation, clot
retraction, and spreading on fibrinogen. The functional
imperfection of Dab2-/- platelets is related to the defect-
ive responses to thrombin-induced RhoA-ROCKII and
Akt-mTOR activation, ADP release and integrin αIIbβ3
activation [9]. Although Dab2 elicits a restrictive func-
tion to the murine platelets stimulated by low concen-
trations of thrombin, defective Dab2 expression has
profound effects on hemostasis and thrombosis in vivo.
Fig. 2 Schematic representation of Dab2 functions in megakaryocytic differentiation and platelet activation. a Dab2 is upregulated during
megakaryocytic differentiation of K562 cells, mESC and CD34+ hematopoietic stem cells and is involved in fibrinogen uptake during megakaryocytic
differentiation. b Dab2 is present in the cytoplasm and α-granules of platelets. By interacting with the intracellular and extracellular portions of αIIbβ3
integrin, Dab2 regulates platelet aggregation and fibrinogen binding induced by various platelet agonists with the exception of thrombin which is the
protease of Dab2. The cleavage of Dab2 by thrombin is protected when Dab2 is associated with sulfatide. c Dab2 regulates the inside-out signaling of
mouse platelets stimulated by low concentrations of thrombin
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is prolonged and thrombus formation is impaired in the
Dab2-/- mice. These findings are consistent with the per-
ception that protease-activated receptors (PAR) 3- and
PAR4-deficient mice, despite eliciting a partial decrease
in thrombin-induced platelet aggregation, are impaired
in hemostasis and are protected against thrombosis
[50, 51]. These studies support the notion that Dab2
is a key regulator in hemostasis and thrombosis.
The consensuses, controversies and future prospects
The study linking Dab2 functions with megakaryocytic
differentiation, platelet signaling and integrin activation
was first reported 15 years ago [31]. The studies up-to-
date support extensively that Dab2 is a regulator ofmegakaryocytic differentiation and platelet function.
Nevertheless, distinctive functions of Dab2 in human
and mouse megakaryocytes and platelets are noted.
Knockdown of Dab2 results in an increase in αIIbβ3 ac-
tivation and cell adhesion to fibrinogen in the K562 cells
[33]. Dab2 is, however, required for murine platelet ag-
gregation and integrin αIIbβ3 activation when the plate-
lets are stimulated by low concentrations of thrombin
[9]. Dab2 negatively regulates human platelet-fibrinogen
interaction and platelet aggregation induced by soluble
agonists except thrombin [10, 47–49]. The complexity in
the abundance and species-specific expression of Dab2
isoforms and the diverse thrombin signaling in human
and murine platelets [6, 9] likely contribute to the
reported heterogeneity of Dab2 function. Alternatively,
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different assay systems being used in these studies. In
the studies of human platelets, recombinant Dab2 pro-
tein was the main tool for analyzing the effects of Dab2
function on platelet response by in vitro experiments
[10, 47–49]. There are no Dab2 mutants or Dab2-
deficient human platelets available for in vivo study. On
the other hand, Dab2-deficient murine platelets have
been generated for analysis of Dab2 function in vivo [9].
An animal model expressing human platelet Dab2
should help us to understand the distinctive Dab2 func-
tions in human and murine platelets.
Dab2 is known as a phosphoprotein in a variety of
cellular processes [12, 25, 33, 40–43]. Due to the lack of
appropriate tools, the physiological functions of Dab2
phosphorylation in platelet signaling have not yet been
elucidated. We have addressed these issues in our recent
work and revealed that Dab2 is phosphorylated during
agonist-stimulated human platelet activation (unpub-
lished data). With the new tools such as CRISPR and
TALEN [52–55] in the generation of genetically modi-
fied animals, the progress in gaining new insights into
the signaling network involving Dab2 expression and
phosphorylation in megakaryocyte, platelet biology and
integrin signaling is expected to accelerate.Conclusions
Multiple functions of platelets in hemostasis, thrombosis,
immunology, cancer progression, microorganism infec-
tions call for considerable attention on understanding
how the activated platelets transmit intracellular signal to
elicit their roles in different biological responses. Extensive
evidence from the studies in the past decades demon-
strates that Dab2 is a key regulator of platelet signaling, in
particular, the endocytosis and the activation of thrombin-
stimulated inside-out signaling of platelet integrin. With
the complicated nature of the signaling network within
megakaryocytes and platelets, the definitive roles of Dab2
in megakaryocytic differentiation, platelet activation and
integrin signaling remain to be explored further.
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